Chordoma Foundation - Systemic Therapy Table

	A	B	D	J	K	L
1	Systemic therapy class	Mechanism of action	Drug	Brand name	Open clinical trial(s)	Available off label

2	Targeted Therapy	EGFR inhibitor	Afatinib	Gilotrif	Yes	Yes
3			Cetuximab	Erbitux	Yes	Yes
4			Gefitinib	Iressa		Yes (not in the U.S.)
5			Erlotinib	Tarceva	Yes	Yes
6			Lapatinib	Tykerb		Yes
7
8		CDK4/6 inhibitor	Palbociclib	Ibrance	Yes	Yes
9					Yes
10
11		CDK9 inhibitor	KB-0742		Yes
12
13		mTOR inhibitor	Sirolimus	Rapamune		Yes
14		mTOR inhibitor	Everolimus	Afinitor		Yes
15			Temsirolimus	Toricel	Yes	Yes
16
17		EZH2 inhibitor	Tazemetostat	Tazverik	Yes
18
19		PDGFR inhibitor	Imatinib	Gleevec		Yes
20			Sorafenib	Nexavar		Yes
21			Sunitinib	Sutent	Yes	Yes
22
23		SINE/XPO1	Selinexor	Xpovio		Yes
24
25		VEGF inhibitor	Regorafenib	Stivarga	Yes	Yes
26					Yes
27			Pazopanib	Votrient		Yes
28			Bevacizumab	Avastin		Yes
29
30	Immune Checkpoint Inhibitor	PD-1/PD-L1 inhibitor	Atezolizumab	Tecentriq		Yes
31			Avelumab	Bavencio		Yes
32			Durvalumab	Imfinzi	Yes	Yes
33			Nivolumab	Opdivo	Yes	Yes
34					Yes
35					Yes
36					Yes
37
38			Pembrolizumab	Keytruda	Yes	Yes
39					Yes
40
41			M7824		Yes
42
43	Therapeutic Vaccine	Anti-brachyury vaccine	GI-6301 vaccine		Yes (on hold)
44
45		Autologous tumor vaccine	MVX-ONCO-1		Yes
46
47	Chemotherapy		INT230-6		Yes
48
49		Anifolate	Pemetrexed	Alimta	Yes	Yes
50
51	To be included in this table, the mechanism of action (MOA) must be: 1. An MOA that the Chordoma Foundation Medical Advisory Board has recommended be explored in a clinical trial for chordoma OR 2. Any MOA that has been studied in a Phase 2 trial for chordoma AND 3. The drugs/therapies listed for each mechanism are either currently being studied in a clinical trial that is enrolling chordoma patients or are available off-label
52
53	© 2018 Chordoma Foundation
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100